Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.026 | 0.7 |
mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |